This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hall, P. A. Articles by Russell, S.E. H. Search for Related Content PubMed PubMed Citation Articles by Hall, P. A. Articles by Russell, S.E. H.

The Septin-Binding Protein Anillin Is Overexpressed in Diverse Human Tumors

Authors' Affiliations: ¹ Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast City Hospital, Belfast, United Kingdom; ² Academic Unit of Pathology, University of Leeds, Leeds, United Kingdom; and ³ Genentech, Inc., South San Francisco, California

Requests for reprints: Peter A. Hall, Centre for Cancer Research and Cell Biology, Queens University Belfast, University Floor, Belfast City Hospital, Belfast, BT9 7AB Northern Ireland, United Kingdom. Phone: 44-28-9063-5397; E-mail: peter.hall{at}qub.ac.uk.

Anillin is an actin-binding protein that can bind septins and is a component of the cytokinetic ring. We assessed the anillin expression in 7,579 human tissue samples and cell lines by DNA microarray analysis. Anillin is expressed ubiquitously but with variable levels of expression, being highest in the central nervous system. The median level of anillin mRNA expression was higher in tumors than normal tissues (median fold increase 2.58; 95% confidence intervals, 2.19-5.68, P < 0.0001) except in the central nervous system where anillin mRNA levels were lower in tumors. We developed a sensitive reverse transcription-PCR strategy to show that anillin mRNA is expressed in cell lines and in cDNA panels derived from fetal and adult tissues, thus validating the microarray data. We compared anillin with Ki67 mRNA expression and found a significant linear relationship between anillin and Ki67 mRNA expression (Spearmann r 0.6, P < 0.0001). Anillin mRNA expression was analyzed during tumor progression in breast, ovarian, kidney, colorectal, hepatic, lung, endometrial, and pancreatic tumors and in all tissues there was progressive increase in anillin mRNA expression from normal to benign to malignant to metastatic disease. Finally, we used anti-anillin sera and found nuclear anillin immunoreactivity to be widespread in normal tissues, often not correlating with proliferative compartments. These data provide insight into the existence of nonproliferation-associated activities of anillin and roles in interphase nuclei. Thus, anillin is overexpressed in diverse common human tumors, but not simply as a consequence of being a proliferation marker. Anillin may have potential as a novel biomarker.